AXS-12

Rx-AXSM-2705AXSM/FDA decisionResearch

Axsome Therapeutics · cataplexy in narcolepsyMay 1, 2027 target

Will the FDA approve AXS-12 for cataplexy in narcolepsy?

Drug profile Company Event Small moleculeNCT05059223

Primary source

YAXSM

AXSM-YES/ USDC

Outcome claim / Research candidate

NOT LISTED

Executable price

—

Change across observed prices in this window

Implied YES probability—Price-based, not a clinical forecast

Market not listed

No market price yet.

This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.

0 trading observationsNo live price feed

YES —NO —

This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.

Rx-AXSM-2705 / Evidence

Unlisted

Pool price—No deployed pool

Dated model P(YES)—No dated model artifact

Days to sponsor target180Date-only guidance

Source publishedJul 15, 2026

Research snapshotOct 28, 2026

FDA targetMay 1, 2027

Small moleculeNCT05059223

A pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.

Program overview

Sponsor identifies AXS-12 as reboxetine and reports a May 1, 2027 FDA target for cataplexy in narcolepsy.

THERAPEUTIC AREANeuroscience

DRUG / PROGRAMAXS-12

INDICATIONcataplexy in narcolepsy

REGULATORY TARGETMay 1, 2027

Agent model / unavailable

No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.

What matters

Longer capital lock-up; approval of another Axsome product cannot satisfy this question.
Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.

Try virtual trading